Study Progress on Serogroup B Meningococcal Vaccine / 中国疫苗和免疫
Chinese Journal of Vaccines and Immunization
;
(6)2008.
Article
Dans Chinois
| WPRIM
| ID: wpr-596763
ABSTRACT
Meningococcal disease,caused by Neisseria meningitidis (Nm),is still one serious threatening infectious disease with high mortality.Vaccination is available for prevention and control of such disease.Based on the chemical structure of capsule polysaccharide,Nm strains were classified into 13 serogroups.Meningococcal polysaccharide vaccines and polysaccharide conjugated protein vaccine against serogroup A,C,W 135 and Y were efficacious and have been widely used.Because of poor immunogenicity and the structurally homologous with neural cell,capsule polysaccharide of serogroup B Nm can not be used as vaccine candidate.In last several decades,B group vaccines develoment focused on the proteins research.Based on the out membrane protein and reverse vaccinology technology,progress of B group vaccine were accelerated.Several meningococcal B vaccine showed favorable immunogenicity and efficacity.Some B vaccines have been licensed and widely used.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Vaccines and Immunization
Année:
2008
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS